Template:Tamoxifen dosage and incidence of breast symptoms with bicalutamide in men
Jump to navigation
Jump to search
| Follow-up timepoint |
Tamoxifen dosage | |||||
|---|---|---|---|---|---|---|
| Placebo | 1 mg/day | 2.5 mg/day | 5 mg/day | 10 mg/day | 20 mg/day | |
| 0 months | –
| |||||
| 6 months | 98% | 90% | 80% | 54% | 22% | 10% |
| 12 months | 99% | 95% | 84% | 56% | 38% | 19% |
| Notes: Prevention of breast symptoms—specifically gynecomastia and breast pain—induced by 150 mg/day bicalutamide monotherapy with tamoxifen in 282 men with prostate cancer. Bicalutamide and tamoxifen were initiated at the same time (0 months). Sources: [1][2] | ||||||
Template documentationReferences
- ↑ Fentiman IS (January 2018). "Managing Male Mammary Maladies". Eur J Breast Health. 14 (1): 5–9. doi:10.5152/ejbh.2017.3841. PMC 5758064. PMID 29322112.
- ↑ Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S (July 2007). "Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study". Eur. Urol. 52 (1): 106–14. doi:10.1016/j.eururo.2007.01.031. PMID 17270340.